Total Payments
$1.8M
2024 Payments
$411,514
Companies
33
Transactions
3,831
Medicare Patients
17,521
Medicare Billing
$5.7M
Payment Breakdown by Category
Other$1.6M (88.1%)
Travel$99,168 (5.4%)
Consulting$67,649 (3.7%)
Food & Beverage$51,742 (2.8%)
Research$1,000 (0.1%)
Education$409.36 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.6M | 623 | 88.1% |
| Travel and Lodging | $99,168 | 606 | 5.4% |
| Consulting Fee | $67,649 | 15 | 3.7% |
| Food and Beverage | $51,742 | 2,570 | 2.8% |
| Unspecified | $1,000 | 1 | 0.1% |
| Education | $409.36 | 16 | 0.0% |
Payments by Type
General
$1.8M
3,830 transactions
Research
$1,000
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Neurocrine Biosciences, Inc. | $441,675 | 667 | $0 (2024) |
| Alkermes, Inc. | $345,401 | 407 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $188,583 | 350 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $141,111 | 417 | $0 (2024) |
| ITI, Inc. | $140,851 | 182 | $0 (2023) |
| ABBVIE INC. | $140,160 | 190 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $134,914 | 504 | $0 (2022) |
| ACADIA Pharmaceuticals Inc | $93,494 | 124 | $0 (2024) |
| Avanir Pharmaceuticals, Inc. | $71,486 | 167 | $0 (2022) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $66,857 | 95 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $411,514 | 726 | Teva Pharmaceuticals USA, Inc. ($99,877) |
| 2023 | $299,278 | 668 | Neurocrine Biosciences, Inc. ($107,122) |
| 2022 | $245,976 | 494 | Neurocrine Biosciences, Inc. ($73,822) |
| 2021 | $204,649 | 464 | Neurocrine Biosciences, Inc. ($60,839) |
| 2020 | $73,343 | 257 | Alkermes, Inc. ($27,509) |
| 2019 | $176,069 | 435 | Alkermes, Inc. ($94,942) |
| 2018 | $193,482 | 389 | Sunovion Pharmaceuticals Inc. ($66,107) |
| 2017 | $240,817 | 398 | Avanir Pharmaceuticals, Inc. ($70,970) |
All Payment Transactions
3,831 individual payment records from CMS Open Payments — Page 1 of 154
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,140.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,656.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,380.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,760.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $2.32 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/19/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: Neuropsychiatry | ||||||
| 12/19/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $5.60 | General |
| Category: Neuropsychiatry | ||||||
| 12/17/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $14.11 | General |
| Category: Neuroscience | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,220.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $123.12 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/16/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $2.58 | General |
| Category: PSYCHIATRY | ||||||
| 12/13/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $22.20 | General |
| Category: PSYCHIATRY | ||||||
| 12/13/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $2.01 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Consulting Fee | Cash or cash equivalent | $6,750.00 | General |
| Category: Neuropsychiatry | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: Neuropsychiatry | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $137.32 | General |
| Category: Neuropsychiatry | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $129.98 | General |
| Category: Neuropsychiatry | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $125.96 | General |
| Category: Neuropsychiatry | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $109.28 | General |
| Category: Neuropsychiatry | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $48.00 | General |
| Category: Neuropsychiatry | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $14.61 | General |
| Category: Neuropsychiatry | ||||||
| 12/12/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $12.34 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $3.84 | General |
| Category: Neuropsychiatry | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,220.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/11/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $1.16 | General |
| Category: PSYCHIATRY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CHARISMA | Neurocrine Biosciences, Inc. | $1,000 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 3,886 | 22,222 | $1.9M | $1.3M |
| 2022 | 18 | 4,266 | 24,267 | $2.3M | $1.4M |
| 2021 | 18 | 4,787 | 25,332 | $2.3M | $1.5M |
| 2020 | 16 | 4,582 | 26,363 | $2.1M | $1.4M |
Total Patients
17,521
Total Services
98,184
Medicare Billing
$5.7M
Procedure Codes
68
All Medicare Procedures & Services
68 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 415 | 9,760 | $780,720 | $581,563 | 74.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 1,390 | 8,969 | $807,210 | $509,766 | 63.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 342 | 1,225 | $128,415 | $100,677 | 78.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 348 | 360 | $72,000 | $46,105 | 64.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 372 | 434 | $45,570 | $35,727 | 78.4% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 385 | 452 | $22,600 | $16,898 | 74.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 212 | 459 | $25,245 | $15,384 | 60.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 78 | 94 | $12,690 | $8,866 | 69.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 92 | 103 | $12,875 | $7,555 | 58.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 56 | 56 | $12,040 | $7,439 | 61.8% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 88 | 155 | $10,850 | $6,421 | 59.2% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Office | 2023 | 18 | 18 | $2,970 | $2,328 | 78.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 29 | 31 | $1,860 | $1,458 | 78.4% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 20 | 21 | $1,890 | $1,314 | 69.5% |
| 99307 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes | Office | 2023 | 21 | 29 | $1,305 | $739.25 | 56.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 20 | 56 | $1,015 | $529.38 | 52.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 404 | 10,618 | $849,440 | $566,041 | 66.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 1,434 | 9,043 | $813,870 | $519,847 | 63.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 371 | 992 | $104,160 | $75,486 | 72.5% |
| 90868 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | Office | 2022 | 15 | 453 | $276,330 | $59,577 | 21.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 338 | 359 | $71,700 | $49,924 | 69.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 352 | 392 | $41,160 | $30,822 | 74.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 365 | 784 | $43,120 | $25,619 | 59.4% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2022 | 116 | 461 | $31,809 | $17,890 | 56.2% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 358 | 427 | $21,350 | $12,316 | 57.7% |
About Dr. Robert Morton, MD
Dr. Robert Morton, MD is a Psychiatry healthcare provider based in Ada, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336222504.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Morton, MD has received a total of $1.8M in payments from pharmaceutical and medical device companies, with $411,514 received in 2024. These payments were reported across 3,831 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.6M).
As a Medicare-enrolled provider, Morton has provided services to 17,521 Medicare beneficiaries, totaling 98,184 services with total Medicare billing of $5.7M. Data is available for 4 years (2020–2023), covering 68 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Ada, OK
- Active Since 10/23/2006
- Last Updated 03/07/2023
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1336222504
Products in Payments
- INGREZZA (Drug) $435,510
- CAPLYTA (Drug) $207,707
- ARISTADA (Drug) $168,851
- VRAYLAR (Drug) $167,423
- LATUDA (Drug) $134,694
- INVEGA SUSTENNA (Drug) $125,478
- Aristada 441 mg (Drug) $94,918
- NUPLAZID (Drug) $93,494
- Austedo XR (Drug) $92,910
- LYBALVI (Drug) $81,524
- NUEDEXTA (Drug) $71,713
- UZEDY (Drug) $67,452
- AUSTEDO (Drug) $27,880
- FANAPT (Drug) $23,844
- COBENFY (Drug) $20,778
- INVEGA TRINZA (Drug) $15,462
- REXULTI (Drug) $2,457
- ABILIFY MAINTENA (Drug) $1,098
- TRINTELLIX (Drug) $1,009
- Qelbree (Drug) $617.15
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Ada
Everett Bayne, M.d, M.D
Psychiatry — Payments: $368.92
Psychiatry $368.92
Benjamin Johnson
Psychiatry — Payments: $238.83
Psychiatry $238.83
Christie Snow, M.d, M.D
Psychiatry — Payments: $129.76
Psychiatry $129.76
Ronald Pence, Md, MD
Psychiatry
Psychiatry
Dr. Marilynn Holman, Md, MD
Psychiatry
Psychiatry
Dr. Kayleb Koslowsky, Md, MD
Psychiatry
Psychiatry